- Home
- FG vs RYTM Comparison
FG vs RYTM Comparison
Compare FG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FG
- RYTM
- Stock Information
- Founded
- FG 1959
- RYTM 2008
- Country
- FG United States
- RYTM United States
- Employees
- FG N/A
- RYTM N/A
- Industry
- FG Life Insurance
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FG Finance
- RYTM Health Care
- Exchange
- FG Nasdaq
- RYTM Nasdaq
- Market Cap
- FG 4.4B
- RYTM 4.3B
- IPO Year
- FG N/A
- RYTM 2017
- Fundamental
- Price
- FG $31.72
- RYTM $61.99
- Analyst Decision
- FG Hold
- RYTM Strong Buy
- Analyst Count
- FG 3
- RYTM 12
- Target Price
- FG $44.33
- RYTM $76.75
- AVG Volume (30 Days)
- FG 184.1K
- RYTM 544.7K
- Earning Date
- FG 08-04-2025
- RYTM 08-05-2025
- Dividend Yield
- FG 2.78%
- RYTM N/A
- EPS Growth
- FG 91.46
- RYTM N/A
- EPS
- FG 3.84
- RYTM N/A
- Revenue
- FG $5,139,000,000.00
- RYTM $136,863,000.00
- Revenue This Year
- FG N/A
- RYTM $37.56
- Revenue Next Year
- FG $19.03
- RYTM $74.99
- P/E Ratio
- FG $8.24
- RYTM N/A
- Revenue Growth
- FG N/A
- RYTM 48.88
- 52 Week Low
- FG $30.10
- RYTM $39.46
- 52 Week High
- FG $50.75
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- FG 45.17
- RYTM 47.67
- Support Level
- FG $30.95
- RYTM $60.70
- Resistance Level
- FG $32.86
- RYTM $62.65
- Average True Range (ATR)
- FG 0.70
- RYTM 2.39
- MACD
- FG -0.00
- RYTM -0.52
- Stochastic Oscillator
- FG 28.84
- RYTM 14.04
About FG F&G Annuities & Life Inc.
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.